Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel and Cetuximab in HNSCC after Pembrolizumab failure
NCT04278092Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Feb 2020
- Primary completion
- Oct 2024
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of paclitaxel, cetuximab in head and neck squamous cell carcinoma (HNSCC), sponsored by Medical University of Vienna. Started Feb 2020; status: completed.
02
Drugs
paclitaxelcetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04278092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04278092.